Skip to main content

Advertisement

Table 3 Treatment data and outcome

From: First clinical experience in 14 patients treated with ADVOS: a study on feasibility, safety and efficacy of a new type of albumin dialysis

  Treat-ment time [min] [19] Serum bilirubin [mg/dl] Serum creatinine [mg/dl] Serum BUN [mg/dl] No. of treatments 28d survival
  Day before ADVOS Before start of ADVOS After ADVOS Delta [mg/dl] Day before ADVOS Before start of ADVOS After ADVOS Delta [mg/dl] Day before ADVOS Before start of ADVOS After ADVOS Delta [mg/dl]   
Patient
P1 745 37.4 41.1 25.4 −15.7 0.7 0.8 0.5 −0.3 59 76 28 −48 19 -
P2 800 22.8 24.0 12.8 −11.2 1.0 1.0 0.9 −0.1 26 25 14 −11 10 -
P3 730 20.8 22.3 14.1 −8.2 1.8 1.6 1.5 −0.1 21 20 18 −2 7 -
P4 770 16.3 15.9 13.2 −2.7 2.4 1.9 1.5 −0.4 27 20 18 −2 29 -
P5 800 n.d. 11.6 9.2 −2.4 n.d. 2.8 1.2 −1.6 n.d. 45 13 −32 3 -
P6 600 43.5 41.6 34.2 −7.4 3.9 3.3 2.2 −1.1 91 97 63 −34 22 +
P7 720 3.1 5.3 3.9 −1.4 1.7 3.0 2.1 −0.9 19 33 22 −11 17 +
P8 420 21.6 20.7 17.8 −2.9 1.3 2.0 2.8 +0.8 44 69 82 +13 9 -
P9 570 26.4 26.2 20.3 −5.9 1.9 2.3 1.7 −0.6 43 51 35 −16 6 +
P10 300 1.9 2.0 1.5 −0.5 1.7 1.3 0.7 −0.6 54 31 16 −15 1 -
P11 240 40.4 41.6 29.0 −12.6 3.0 3.2 2.0 −01.2 35 40 27 −13 101 +
P12 510 18.3 17.5 10.9 −6.6 1.4 2.9 2.1 −0.8 40 49 27 −22 3 -
P13 360 38.2 42.1 19.9 −22.2 3.0 2.3 1.2 −1.1 79 68 33 −35 11 +
P14 480 49.3 51.8 35.7 −16.1 3.0 3.0 2.2 −0.8 54 67 39 −28 1 -
Mean ± SD Number [%] 575± 193 26.2± 14.9 26.0± 15.4 17.7± 10.5 −8.3± 6.5 2.0± 0.9 2.2± 0.8 1.6± 0.7 −0.6± 0.6 46± 22 49± 23 31± 20 −18± 16 17± 26 [1–101] 5/14 [36%]
  1. ADVOS advanced organ support
  2. BUN blood urea nitrogen
  3. n.d. not done
  4. Delta absolute changes when comparing values immediately before and after the first ADVOS session